As a simple hypothetical example: if enhanced H 2 O 2 drives oxidation of 2 GSH to GSSG at 20 nmol.g 1 FW min 1 (which even if one considers only DHAR as a source of GSSG is no more than 1% of typical capacities measured in vitro ) but the in vivo GR activity is 1% slower (19.8 nmol.g 1 FW min 1
While alternative administration routes, such as intravenous, intramuscular, nasal, percutaneous, and transdermal delivery, have shown promise in certain conditions, these methods can be invasive and uncomfortable for patients
Notably, the -glutamyl-CA1 region of GSH interacts relatively weakly with OsDHAR and shows poor electron density
It's like having a cleanup crew that works 24/7
While tripeptides have been introduced as promising therapeutic agents in earlier sections, this part contrasts their therapeutic potential with larger peptides, based on their physicochemical characteristics and performance in wound healing models